ENGINEERED THERMOSTABLE CARBONIC ANHYDRASE ENZYMES

Abstract

Disclosed herein are compositions and methods for making and using improved carbonic anhydrases for novel, sustainable, and low energy CO.sub.2 waste gas scrubbing technologies that are also transformational carbon capture technologies. Embodiments of methods, systems and compositions disclosed herein include, but are not limited to, non-aqueous solvents, advanced membranes, sorbents, and cryogenic systems that significantly reduce the cost of CO.sub.2 capture from coal and natural gas-fired power plants and industrial facilities. Methods disclosed herein reduce the energy and cost required for CO.sub.2 separation and can be applied for both pre-combustion and post-combustion CO.sub.2 capture.

Claims

1. A non-naturally occurring carbonic anhydrase comprising at least one mutation that results in the substitution of at least one cysteine for at least one amino acid in a naturally occurring carbonic anhydrase; and wherein the non-naturally occurring carbonic anhydrase has increased activity at a temperature of greater than about 60 degrees Celsius when compared to the naturally occurring carbonic anhydrase.

2. The non-naturally occurring carbonic anhydrase of claim 1 wherein the increased activity is for more than about 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 24 hours, 44 hours, 48 hours, and 92 hours.

3. The non-naturally occurring carbonic anhydrase of claim 1 wherein the increased activity is at a temperature greater than 65, 70, 75, 80, 85 or 90 degrees Celsius.

4. The non-naturally occurring carbonic anhydrase of claim 1 wherein a nucleotide sequence encoding the non-naturally occurring carbonic anhydrase comprises a sequence that is greater than 70% identical to a sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 22, SEQ ID NO: 24 and SEQ ID NO: 26.

5. The non-naturally occurring carbonic anhydrase of claim 1 comprising an amino acid sequence that is greater than 70% identical to a sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 21, SEQ ID NO: 23 and SEQ ID NO: 25.

6. A method for CO.sub.2 separation and CO.sub.2 capture comprising the step of reacting CO.sub.2 with a non-naturally occurring carbonic anhydrase comprising at least one mutation that results in the substitution of at least one cysteine for at least one amino acid in a naturally occurring carbonic anhydrase; and wherein the non-naturally occurring carbonic anhydrase has increased activity at a temperature of greater than about 60 degrees Celsius when compared to the naturally occurring carbonic anhydrase.

7. The method of claim 6 wherein the step of reacting CO.sub.2 with non-naturally occurring carbonic anhydrase is for more than about 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 24 hours, 44 hours, 48 hours, and 92 hours.

8. The method of claim 6 wherein the step of reacting CO.sub.2 with the non-naturally occurring carbonic anhydrase is at a temperature greater than 65, 70, 75, 80, 85 or 90 degrees Celsius.

9. The method of claim 6 wherein the non-naturally occurring carbonic anhydrase comprises a nucleotide sequence that is greater than 70% identical to a sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 22, SEQ ID NO: 24 and SEQ ID NO: 26.

10. The method of claim 6 wherein the non-naturally occurring carbonic anhydrase comprises an amino acid sequence that is greater than 70% identical to a sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 21, SEQ ID NO: 23 and SEQ ID NO: 25.

11. A system for CO.sub.2 separation and CO.sub.2 capture comprising s non-naturally occurring carbonic anhydrase comprising at least one mutation that results in the substitution of at least one cysteine for at least one amino acid in a naturally occurring carbonic anhydrase; and wherein the non-naturally occurring carbonic anhydrase has increased activity at a temperature of greater than about 60 degrees Celsius when compared to the naturally occurring carbonic anhydrase; and wherein the system further comprises a support wherein the with the non-naturally occurring carbonic anhydrase is immobilized to the support; and wherein the non-naturally occurring carbonic anhydrase is contacted with CO.sub.2.

12. The system of claim 11 wherein the non-naturally occurring carbonic anhydrase has increased activity for more than about 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 24 hours, 44 hours, 48 hours, and 92 hours.

13. The system of claim 11 wherein the non-naturally occurring carbonic anhydrase reacts with CO.sub.2 at a temperature greater than 65, 70, 75, 80, 85 or 90 degrees Celsius.

14. The system of claim 11 wherein the CO.sub.2 to be separated and captured results from the combustion of fossil fuels or biomass.

15. The system of claim 11 further comprising a carbon capture unit wherein the carbon capture unit comprises an immobilized biocatalyst comprising an amino acid sequence that is greater than 70% identical to a sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 21, SEQ ID NO: 23 and SEQ ID NO: 25.

Description

DESCRIPTION OF THE DRAWINGS

[0012] FIGS. 1A and 1B depict a dimer of PmaCA. Two protein molecules are shown in cartoon representation and colored grey and green. Blue balls represent zinc ion located at the active sites of each molecule. FIG. 1A, frontal view. FIG. 1B, view from above, rotated 90 degrees.

[0013] FIGS. 2A and 2B depict a TaCA tetramer. FIG. 2AFour protein molecules are shown in cartoon representation and colored as green, magenta, orange, and cyan. Blue balls represent zinc ion located at the active sites of each molecule. FIG. 2Bzoom-in on the disulfide bonds connecting protein molecules in the tetramer in a crisscross fashion.

[0014] FIG. 3 depicts a superimposition of PmaCA (grey), SspCA (cyan), SazCA (yellow), LogaCA (green), and TaCA (magenta). Proteins are superimposed using one protein chain for each (upper right). The fold is conserved, and the dimerization interface is also conserved.

[0015] FIG. 4 depicts mutant 1: Gly200Cys, Asn236Cys. View from above. Two disulfides connecting molecules in the dimer are shown as spheres.

[0016] FIG. 5 depicts mutant 2, frontal view: Ala61Cys (makes disulfide with the same Ala61Cys from the 2nd molecule), one disulfide connecting molecules in the dimer is shown as spheres.

[0017] FIG. 6 depicts mutant 3: Ser189Cys, Ala237Cys, view from above. Two disulfides connecting molecules in the dimer are shown as spheres.

[0018] FIG. 7 depicts a sequence alignment for TaCA, PmaCA, LogaCA, SspCA, SazCA and PmaCA mutants 1, 2, and 3. Positions of point mutations are boxed in red for mutant 1, blue for mutant 2, green for mutant 3 indicating where these mutations should be introduced in other CAs.

[0019] FIG. 8 depicts activity retained after PmaCA WT and mutants incubation at 60? C. for 2 hours.

[0020] FIG. 9 depicts activity retained after PmaCA WT and mutants incubation at 90? C. The proteins were induced and expressed at 35? C. and 45? C. temperatures. Mutants 1, 3, and 2+3 combo did not have high broth activity from the beginning, so the activity of these samples quickly dropped below the method detection range. Despite sharp activity decline in the first hour for the Mutant 2, in the long run (2-48 h range) this mutant retained more activity than the WT.

[0021] FIG. 10 depicts activity retained after PmaCA WT and mutants incubation at 90? C. The proteins were induced and expressed at 35? C. and 45? C. temperatures as in Experiment 2. Protein containing broths were concentrated to boost the initial absolute activity numbers. Mutants 1, 3, and 2+3 combo did not have high broth activity from the beginning, so the activity of these samples quickly dropped below the method detection range. At 1 hour mutant 2 already retained higher activity than WT enzyme and in interval 2-72 hours mutant 2 retained significant margin above WT activity. The broth for PmaCA WT enzyme expressed at 45? C. was treated differently from other broths. It was overconcentrated first and then diluted with distilled water to reach the absolute activity levels comparable to other broths.

[0022] FIG. 11 depicts activity retained after SazCA WT and mutants 2, 3, and 2+3 combination incubation at 90? C. Proteins were induced and expressed at 45? C. Initial sharp drop of activity within 1st hour could be attributed to the degradation of the portion of a protein that was not able to fold correctly. Since mutant 2 has one single point mutation, mutant 3 has two single point mutation and mutant 2+3 has three single point mutations, without being limited by theory, it is possible that negative effects from the mutations are stacked up and the yield of the properly folded protein decreases with the increase of the number of mutations. After an initial sharp drop, activity is decreasing much slower for the mutants than it is decreasing for the WT enzyme. If we consider the first hour at 90? C. as pre-incubation and take activities after 1 hour as 100% for each protein, the retained activity graphs would show the improved stability of the mutants.

[0023] FIG. 12 depicts activity retained after SazCA WT and mutants 2, 3, and 2+3 combination incubation at 90? C. when activity after 1 hour of pre-incubation is taken as 100%.

[0024] FIG. 13 depicts activity retained after SspCA WT and mutants incubation at 90? C. The proteins were induced and expressed at 35? C. and 45? C. temperatures as in Experiment 2. Protein containing broths were concentrated to boost the initial absolute activity numbers. At five hours, mutant samples were the best performing, retaining about 40% of initial activity.

[0025] FIG. 14 depicts SDS-PAGE analysis of CA6FL protein expressed in B. subtilis guided by signal peptide of B. licheniformis alpha-amylase (SPamyL) at 35? C. Lanes 1-3 were the secreted proteins collected at 0, 6 and 12 hours after IPTG induction, respectively. The loading amount is 20 ?L (i.e. 15 ?L supernatant+5 ?L 4?LDS) per well in non-reducing SDS-PAGE. The red box indicated the expression of CA6FL bands.

[0026] FIG. 15 depicts fresh broth activity for PmaCA (CA3) WT and mutants induced at 30? C., 35? C., and 45? C. Activity for the mut1, mut3, and mut23 (combination of mutants 2 and 3) was below the measurable threshold for the set induced at 30? C.

[0027] FIG. 16 depicts fresh broth activity for LogaCA (CA4) WT and mutants induced at 35? C. and 45? C. Activity for the mut3 and mut23 (combination of mutants 2 and 3) was below the measurable threshold for the set induced at 35? C.

[0028] FIG. 17 depicts fresh broth activity for SspCA (CA5) WT and mutants induced at 35? C. and 45? C.

[0029] FIG. 18 depicts fresh broth activity for SazCA (CA6) WT and mutants induced at 35? C. and 45? C.

[0030] FIG. 19 depicts fresh broth activity for PmaCA (CA3) WT and mutants induced at 45? C. with and without addition of cysteine. Activity for the mut1 was below the measurable threshold for the set induced with or without cysteine. Activity for the mut23 (combination of mutants 2 and 3) was below the measurable threshold for the set induced without cysteine.

[0031] FIG. 20 depicts fresh broth activity for PmaCA (CA3) WT and mutants induced at 45? C. with and without addition of cysteine, amino acid mix, or both. Activity for the mut23 (combination of mutants 2 and 3) was below the measurable threshold for the set induced without cysteine.

[0032] FIG. 21 depicts fresh broth activity for PmaCA (CA3) WT and mutants induced at 45? C. with and without addition of diamide. Activity for the mut1, and mut23 (combination of mutants 2 and 3) was below the measurable threshold.

DETAILED DESCRIPTION

[0033] Being one of the fastest enzymes known in nature, carbonic anhydrase (CA) catalyzes the interconversion between CO.sub.2 and bicarbonate which accelerates the capture of CO.sub.2 by serving as a catalyst in alkaline capture solvents with slow absorption kinetics. The enzyme accelerated process allows use of more benign and sustainable solvents with low regeneration energy thus reducing energy consumption.

[0034] Disclosed herein are CA enzyme candidates with improved catalytic activity, thermostability and solvent compatibility and developed new enzyme immobilization techniques for improving the enzyme longevity and tested more benign and sustainable solvents accelerated by CA for CO.sub.2 capture. The improved enzyme properties together with the novel immobilization technology with selected solvents have the potential to significantly reduce the cost and the energy requirement for CO.sub.2 capture.

[0035] Disclosed herein are optimized, highly active and thermostable carbonic anhydrase enzymes, which are needed for testing in a novel and low energy CO.sub.2 scrubbing process. CA is gaining credibility as an efficient catalyst for significantly enhancing reactive CO.sub.2 absorption in low energy solvents. To overcome the high energy requirement of traditional monoethanolamine (MEA)-based CO.sub.2 scrubbing process, disclosed herein are methods, compositions and systems used to develop more efficient CO.sub.2 scrubbing technology by: 1) improving the robustness of CA, including tolerance to high temperature, high solvent concentration and high pH; 2) improving CA longevity using biodegradable enzyme-entrapping polymeric structures (BEEPS); and 3) utilizing environmentally friendly solvents to improve process sustainability.

[0036] The most studied CA family currently is alpha-class of CAs with at least five members of the family being characterized biochemically and structurally: [0037] a) Thermovibrio ammonificansTaCA, CA1 [0038] b) Persephonella marina EX-H1PmaCA, CA3 [0039] c) another Persephonella marina CA coming from metagenome sampling at Logachev deep sea ventLogaCA, CA4 [0040] d) Sulfurihydrogenibium yellowstonense YO3AOP1-SspCA, CA5 [0041] e) Sulfurihydrogenibium azorenseSazCA, CA6

[0042] While active site organization of the listed above alpha-class CAs is suited for an independent monomeric function, it seems that all examples (except for TaCA) exist as dimers in the solution, see FIG. 1, for example.

[0043] In, for example FIG. 1, the dimerization interface has significant area and is stabilized by hydrophobic interactions, hydrogen bonds and salt bridges. There are no covalent bonds between protein molecules on the dimerization interface. The protein fold is conserved throughout the family and the dimerization interface shares very high similarity among the listed enzymes.

[0044] In an embodiment, disclosed herein are novel protein dimers of alpha-CAs via one or more covalent disulfide bonds designed at the dimerization interface via one or more single-point mutations, replacing a native amino acid residue of the enzyme with cysteine. The exact locations of the single-point mutation may be used in alpha-CAs from different species. Three locations for the intermolecular disulfides were designed in the first round, in an embodiment, PmaCA numbering (including signal peptide, SP) is reflected in FIG. 7.

[0045] In an embodiment, mutants 1, 2, 3, and 2+3 combination were introduced in PmaCA and 2, 3, and 2+3 in SazCA. For SazCA mutant 1 is Gly210Cys+Asn246Cys (numbering according to the full-length sequence including signal peptide), mutant 2 is Ala71Cys, mutant 3 is Ser199Cys+Ser247Cys. Wild-type (WT) enzymes along with the mutants were expressed in Bacillus subtilis and induced at 35? C. and 45? C. temperatures. Culturing media containing secreted enzymes (broth) was collected, cells were spun down and removed. All enzymes were subjected to the prolonged incubation at 90? C. in form of the broth. Samples were taken out at 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 24 hours, 44-48 hours, and 92 hours. Samples were immediately cooled down to 0? C. and the enzyme activity was tested by Wilbur-Anderson method using colorimetric assay.

[0046] Assay description: In an embodiment, an assay is performed on ice at 0? C.-1? C. temperature. All solutions are chilled on ice until the desired temperature is reached. 1 mL of the 20 mM Tris buffer at pH 8.3 was mixed with 0.1 mL pH indicator Bromthymol Blue (BTB). Ten uL (0.01 mL) of broth containing enzyme was added to the mix (nothing added for the control). Then, 1 mL of water fully saturated with CO.sub.2 was added and the stopwatch was started. When BTB changed color from blue to yellow indicating pH dropping below 6.3, stopwatch was stopped. Uncatalyzed reaction time (T.sub.o) is longer than catalyzed reaction time (T.sub.c) when an activity catalyst is present. Activity in Wilbur-Anderson units is calculated as WAU=(T.sub.o?T.sub.c)/T.sub.c.

[0047] For the comparison of different enzymes broth activity, this WAU value is then normalized for the dilution factor (DF=V.sub.tot/V.sub.broth where V.sub.tot is a total reaction volume and V.sub.broth is the volume of broth added) and optical density of the broth (OD), so the units to compare would be WAU*DF/OD.

[0048] For the measurement of retained activity, WAU value of each enzyme at start is taken as 100% for that particular enzyme, and WAU values obtained after various incubation times are compared to the initial WAU activity value.

[0049] As an example, results for PmaCA enzymes set are depicted in FIG. 8.

[0050] To be effective for CO.sub.2 sequestration, CA enzymes need to withstand harsh process conditions, high temperature, high pH, high solvent conditions and tolerance of gas and process contaminants. In an embodiment, the non-naturally occurring CA enzymes disclosed herein 1) improve enzyme robustness including thermotolerance of CA enzymes with fast CO.sub.2 absorption rate, thermostability and solvent compatibility; 2) improve CA longevity using biodegradable enzyme-entrapping polymeric structures (BEEPS); and 3) utilize compatible environmentally friendly solvents to improve process sustainability with lower energy requirement. Thus, disclosed herein are engineered, non-naturally occurring CA enzymes with improved properties including catalytic activity, thermostability and solvent compatibility.

[0051] In an embodiment, a large quantity of the improved CA enzyme candidates is needed for fabricating sufficient immobilized biocatalyst materials using enzyme immobilization technology and further testing at the bench-scale integrated carbon capture unit with selected more benign and sustainable solvents with low regeneration energy. In an embodiment, the system (with an internal diameter of 7.6 cm, a packing height of approximately 2 m) was outfitted with instrumentation to allow comprehensive data gathering on temperature profile along the absorber and stripper column to calculate mass transfer flux and regeneration energy consumption, optimize the enzyme production process for scaling-up the production of the improved CA enzyme candidates; and produce up to 100 g of protein for fabricating immobilized biocatalyst and testing at the integrated carbon capture unit. The improved enzyme properties together with the novel immobilization technology with selected solvents provide substantial reduction of the energy requirement and cost for CO.sub.2 capture. In an embodiment, the compositions, methods and systems disclosed herein provide alternative CO.sub.2 capture technologies which can be deployed in many industrial applications for capturing CO.sub.2 from biopower and fossil-based power plants.

[0052] The data graphically depicted in FIG. 13 are also disclosed in Table 1 below:

TABLE-US-00001 CA5 CA5 CA5 CA5 CA5 CA5 CA5 CA5 Time, WT m2 m3 m23 WT m2 m3 m23 h 35C 35C 35C 35C 45C 45C 45C 45C 0 100 100 100 100 100 100 100 100 3 21.1 53.8 56.8 20.6 30.2 37.9 53.3 23.0 5 0.8 8.5 38.5 8.3 0.0 4.4 39.2 13.9

[0053] The data depicted in FIG. 8 are also disclosed in Table 2 below:

TABLE-US-00002 CA sample Activity retained after 2 hours at 60 C. CA3 WT 14.61 CA3mut1 0.00 CA3mut2 96.24 CA3mut3 95.32

[0054] The data depicted in FIG. 9 are also disclosed in Table 3 below:

TABLE-US-00003 time, h 35C WT 35C m1 35C m2 35C m3 35C m23 45C WT 45C m1 45C m2 45C m3 45 m23 0 100 100 100 100 100 100 100 100 100 100 0.5 42.50 10.08 49.41 11.78 0.00 75.11 0.00 76.70 16.92 0.00 1 16.89 0 32.91 0 40.28 50.40884 0.00 2 11.89 36.11 21.24 48.00 3 0.00 27.25 5.48 45.31 4 27.05 3.04 34.39 6 22.77 0.00 34.80 48 21.95 24.72

[0055] The data depicted in FIG. 10 are also disclosed in Table 4 below:

TABLE-US-00004 Time, CA3 WT CA3 m1 CA3 m2 CA3 m3 CA3m23 CA3 WT CA3 m1 CA3 m2 CA3 m3 CA3m23 h 35C 3 3 3 3 4 4 4 4 45C 0 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 0.5 66.70 6.26 55.26 6.09 0.00 44.08 1.14 57.99 5.37 0.00 1 37.24 0.00 42.48 0.00 11.79 0.00 49.40 0.00 2 18.38 42.42 6.05 43.92 3 16.30 41.67 3.94 41.39 4 12.93 37.84 4.52 40.45 5 15.35 38.74 2.93 43.06 6 18.18 34.87 0.00 42.14 24 13.85 31.56 1.09 30.51 48 6.98 22.80 0.70 23.75 72 1.89 16.64 0.94 18.85 indicates data missing or illegible when filed

EXPERIMENTAL EXAMPLES

B. subtilis Strain and the Preparation of Competent Cells

[0056] B. subtilis strain WB800N strain was obtained from MoBiTec GmbH (Gottingen, Germany), and used as the host strain for extracellular expression of CAs. WB800N strain was an eightfold extracellular protease deficient derivative of strain 168, with genotype of nprE aprE epr bpr mpr::ble nprB::bsr ?vpr wprA::hyg cm::neo; NeoR (i.e. carries resistance to neomycin). The competent cells of WB800N were prepared according to the technical guide provided by the above company.

Expression Vector, the Design of the Constructs for Expressing CAs in B. subtilis

[0057] Bacillus expression vector pHT43 was obtained from MoBiTec GmbH (Gottingen, Germany).

Signal Peptides, Gene Synthesis and Subcloning into Vector to Build the Constructs for Expressing CAs in B. subtilis

[0058] The signal peptide of Bacillus licheniformis alpha-amylase (i.e. AmyL; uniprot ID, P06278) is a 29 aa signal peptide named as SPamyL, MKQQKRLYARLLTLLFALIFLLPHSAAAA (SEQ ID NO: 35); this signal peptide was used for the expression and secretion of CAs.

[0059] The sequence of each CA gene was codon-optimized using B. subtilis codon usage frequency and synthesized by GenScript Inc (Piscataway, New Jersey); it had KpnI site at 5 end, and stop codon-XbaI (taatctaga) at 3 end, and was composed of 87 nucleotides coding for the 29 aa of signal peptide SPamyL, followed by the codon-optimized CA gene sequence, as disclosed herein in SEQ ID NOs 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34.

[0060] For the subcloning, digest the above synthesized gene with KpnI-XbaI, and linked into KpnI-XbaI cut pHT43 vector. The obtained plasmids were used for transformation as described below.

Transformation and Engineered Strains

[0061] These above plasmids plus the empty vector pTH43 were transformed into B. subtilis WB800N competent cells, using the procedure according to the technical guide provided by the above company. The obtained strains were listed in the below table.

TABLE-US-00005 TABLE 5 Plasmids and strains for expressing carbonic anhydrase (CA) enzymes in B. subtilis using WB800N (shorten as strain 800) as host cell. Plasmids with signal peptide and Amino Acid DNA Strains CA description SEQ ID NO. SEQ ID NO. 800-1-EV pHT43 EV 800-CA3 pHT43-SPamyL-PmaCA-CA3 SEQ ID NO: 1 SEQ ID NO: 2 800-CA3mut1 pHT43-SPamyL-PmaCA-CA3mut1 SEQ ID NO: 3 SEQ ID NO: 4 with G181C and N217C 800-CA3mut2 pHT43-SPamyL-PmaCA-CA3mut2 SEQ ID NO: 5 SEQ ID NO: 6 with A42C 800-CA3mut3 pHT43-SPamyL-PmaCA-CA3mut3 SEQ ID NO: 7 SEQ ID NO: 8 with S170C and N217C 800-CA3mut23 pHT43-SPamyL-PmaCA-CA3mut23 SEQ ID NO: 9 SEQ ID NO: 10 800-CA4 pHT43-SPamyL-LOGACA-CA4 SEQ ID NO: 11 SEQ ID NO: 12 800-CA4mut2 pHT43-SPamyL-LOGACA-CA4mut2 SEQ ID NO: 13 SEQ ID NO: 14 800-CA4mut3 pHT43-SPamyL-LOGACA-CA4mut3 SEQ ID NO: 15 SEQ ID NO: 16 800-CA4mut23 pHT43-SPamyL-LOGACA-CA4mut23 SEQ ID NO: 17 SEQ ID NO: 18 800-CA5 pHT43-SPamyL-SspCA-CA5 SEQ ID NO: 19 SEQ ID NO: 20 800-CA5mut2 pHT43-SPamyL-SspCA-CA5mut2 SEQ ID NO: 21 SEQ ID NO: 22 800-CA5mut3 pHT43-SPamyL-SspCA-CA5mut3 SEQ ID NO: 23 SEQ ID NO: 24 800-CA5mut23 pHT43-SPamyL-SspCA-CA5mut23 SEQ ID NO: 25 SEQ ID NO: 26 800-CA6FL pHT43-SPamyL-fullSazCA SEQ ID NO: 27 SEQ ID NO: 28 800-CA6FLmut2 pHT43-SPamyL-fullSazCAmut2 SEQ ID NO: 29 SEQ ID NO: 30 800-CA6FLmut3 pHT43-SPamyL-fullSazCAmut3 SEQ ID NO: 31 SEQ ID NO: 32 800-CA6FLmut23 pHT43-SPamyL-fullSazCAmut23 SEQ ID NO: 33 SEQ ID NO: 34

Expression and Secretion of CA Proteins Induced with IPTG at the Default 35? C.

[0062] Since the plasmids we built contain signal peptide SPamyL, the recombinant CAs were expected to be secreted into the medium. To test the secretion of CAs, obtained transformants were cultured. Briefly, inoculate the recombinant B. subtilis strains from plate or glycerol storage into 5 mL fresh 2xYT medium (16 g/L tryptone, 10 g/L yeast extract, 5 g/L NaCl, final pH 7.0) supplemented with neomycin 10 ?g/mL and chloramphenicol (5 ?g/mL), and cultured in a shaker at 35? C., 210 rpm. Inoculated the above seed culture into 20 mL fresh 2xYT medium supplemented with neomycin 10 ?g/mL and chloramphenicol (5 ?g/mL) in a 125-mL flask to an OD.sub.600 of 0.15. The cultures were grown in a shaker at 35? C., 210 rpm until the OD.sub.600 reached 0.7-0.8, then it was induced with 1 mM IPTG and 0.5 mM ZnSO.sub.4, by which two aliquots of samples being collected and defined as T.sub.0: 100 uL and 1 mL). The cultures were continued to grow in a shaker at 35? C. and 130 rpm.

[0063] Similarly, three aliquots were collected at 6 and 12 h after the induction (defined as T.sub.6 and T.sub.12 samples): 100 ?L and 1 mL. These T.sub.0 and T.sub.12 samples were centrifuged at 12,000 rpm, 10 min, 4? C. to separate the supernatants and pellets. While 100 ?L supernatant was mixed with 33 ?L 4?LDS sample buffer, the pellets from 100 uL culture were suspended in 133 ?L 1?LDS sample buffer; both being heated at 95? C. for 5 min, followed by centrifugation at 12,000 rpm for 2 min to remove any debris. For these protein samples, 20 ?L of each preparation was analyzed with SDS-PAGE.

Expression and Secretion of CA Proteins Induced with IPTG at 30, 35 and 45? C.

[0064] The expression and secretion of CA proteins by the mutants were also examined after being induced at 30, 35 and 45? C. for 12 hours. The procedures for seed culture preparation, the inoculation into the fresh 2XYT and the initial culturing to OD.sub.600 of 0.7-0.8 at the default 35? C. were the same as described in the above section of Expression and secretion of CA proteins induced at the default 35? C.. When the OD.sub.600 reached 0.7-0.8, 1 mM IPTG and 0.5 mM ZnSO.sub.4 (final concentration) were added into 20 mL culture in 125-mL flasks. The flasks were transferred to different shakers set at designated either 30? C., or 35? C., or 45? C., with a speed of 130 rpm for 12 hours. The samples were harvested and centrifuged as described above, with the supernatants being collected and stored at 4? C. until being analyzed for the CA activity, heat treatment and thermostability analyses.

Expression and Secretion of CA Proteins Induced with IPTG with the Supplements of Cysteine or Diamide

[0065] To test if the supplements of cysteine or diamide has any impacts on the folding, secretion and functionality of CA proteins, the expression and secretion of CA proteins by the mutants were investigated after being induced at OD.sub.600 of 0.7-0.8 with a mixture of IPTG and ZnSO.sub.4 without (as the control) or with cysteine or diamide, using the final concentrations as listed below, followed by continuing shaking at 130 rpm at designated 30? C., or 35? C., or 45? C. for 12 hours.

[0066] Treatments with cysteine or diamide supplements (with final concentration added into the medium at OD.sub.600 of 0.7-0.8): [0067] (1). Control treatment: 1 mM IPTG+0.5 mM ZnSO.sub.4 [0068] (2). Cysteine treatment: 1 mM IPTG+0.5 mM ZnSO.sub.4+4 mM cysteine [0069] (3). Diamide treatment: 1 mM IPTG+0.5 mM ZnSO.sub.4+0.25 mM diamide

[0070] By default, the cysteine stock was freshly prepared unless it was indicated otherwise. The diamide stock also was also freshly prepared.

Expression and Secretion of CA6FL as a Representative CA

[0071] SDS-PAGE analysis of the cell supernatants reveal that we have successfully expressed CA6FL as a representative CA with signal peptide SPamyL, Furthermore, 6 h of IPTG induction at 35? C. is sufficient to lead CA6FL expression and secretion at substantial levels, while a longer IPTG induction time to 12 hours led to higher expression and secretion levels of CA6FL (FIG. 14). Thus, 12 h of IPTG induction at 35? C. was more desirable than 6 h IPTG induction.

[0072] In an embodiment, elevated temperature leads to better CA expression in B. subtilis. Experiment 1: Wild-type (WT) enzymes along with the mutants were expressed in Bacillus subtilis and induced at 30? C., 35? C., and 45? C. for PmaCA (CA3), see FIG. 15.

[0073] Experiment 2: Wild-type (WT) enzymes along with the mutants were expressed in Bacillus subtilis and induced at 35? C., and 45? C. for LogaCA, see FIG. 16.

[0074] Experiment 3: Wild-type (WT) enzymes along with the mutants were expressed in Bacillus subtilis and induced at 35? C., and 45? C. for SspCA (CA5), see FIG. 17.

[0075] Experiment 4: Wild-type (WT) enzymes along with the mutants were expressed in Bacillus subtilis and induced at 35? C., and 45? C. for SazCA (CA6), see FIG. 18.

[0076] In an embodiment, addition of free cysteine to the expression media leads to the better CA expression. Experiment 5: Wild-type (WT) enzymes along with the mutants were expressed in Bacillus subtilis and induced at 45? C. for PmaCA (CA3) with and without addition of the cysteine, see FIG. 19.

[0077] Experiment 6: Wild-type (WT) enzymes along with the mutants were expressed in Bacillus subtilis and induced at 45? C. for PmaCA (CA3) with and without addition of the cysteine, see FIG. 20.

[0078] In an embodiment, addition of diamide to the expression media leads to the improved CA expression. Experiment 7: Wild-type (WT) enzymes along with the mutants were expressed in Bacillus subtilis and induced at 45? C. for PmaCA (CA3) with and without addition of the diamide, see FIG. 21.

[0079] The following sequences are embodiments of amino acid and nucleotide sequences representing the genes encoding for engineered CAs disclosed herein.

[0080] SEQ ID NO:1 and SEQ ID NO: 2

[0081] SEQ name: SPamyL-PmaCA-CA3

[0082] LENGTH: 253 for PRT; 762 for DNA

[0083] TYPE: PRT; DNA

[0084] ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; PmaCA-CA3 PRT from Persephonella marina. Synthetic for DNA

TABLE-US-00006 (PRT) SEQIDNO:1 MKQQKRLYARLLTLLFALIFLLPHSAAAAGGGWSYHGEHGPEHWGDLKD EYIMCKIGKNQSPVDINRIVDAKLKPIKIEYRAGATKVLNNGHTIKVSY EPGSYIVVDGIKFELKQFHFHAPSEHKLKGQHYPFEAHFVHADKHGNLA VIGVFFKEGRENPILEKIWKVMPENAGEEVKLAHKINAEDLLPKDRDYY RYSGSLTTPPCSEGVRWIVMEEEMEMSKEQIEKFRKIMGGDTNRPVQPL NARMIMEK (DNA) SEQIDNO:2 ATGAAACAACAGAAAAGACTGTATGCACGCCTGCTTACATTACTGTTTG CTCTTATTTTTCTTTTACCGCATTCAGCAGCGGCTGCCGGCGGAGGATG GAGCTATCATGGCGAACATGGACCTGAACATTGGGGTGACCTGAAAGAC GAATATATTATGTGCAAAATCGGCAAAAATCAATCACCGGTTGATATTA ACAGAATCGTGGATGCAAAACTTAAACCGATCAAAATCGAATATCGCGC AGGAGCGACAAAAGTCCTGAACAACGGCCATACAATCAAAGTTTCTTAT GAACCGGGATCATATATTGTTGTGGATGGCATCAAATTTGAATTAAAAC AATTTCATTTTCATGCACCGAGCGAACATAAACTGAAAGGACAGCATTA TCCGTTTGAAGCTCATTTTGTTCATGCCGATAAACATGGCAATCTGGCT GTCATCGGAGTTTTCTTTAAAGAAGGCAGAGAAAACCCGATTCTTGAAA AAATCTGGAAAGTGATGCCGGAAAATGCCGGCGAAGAAGTCAAATTAGC ACATAAAATCAACGCGGAAGATTTACTGCCGAAAGATAGAGATTATTAT CGCTATTCAGGAAGCCTGACAACACCGCCGTGCAGCGAAGGCGTGAGAT GGATCGTCATGGAAGAAGAAATGGAAATGTCTAAAGAACAGATCGAAAA ATTTCGCAAAATCATGGGAGGCGATACGAACCGTCCTGTGCAGCCGTTG AATGCGAGAATGATTATGGAAAAATAA

[0085] SEQ ID NO:3 and SEQ ID NO: 4

[0086] SEQ name: SPamyL-PmaCA-CA3mut1

[0087] LENGTH: 253 for PRT; 762 for DNA

[0088] TYPE: PRT; DNA

[0089] ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; PmaCA-CA3mut1 modified from Persephonella marina.

TABLE-US-00007 (PRT) SEQIDNO:3 MKQQKRLYARLLTLLFALIFLLPHSAAAAGGGWSYHGEHGPEHWGDLKD EYIMCKIGKNQSPVDINRIVDAKLKPIKIEYRAGATKVLNNGHTIKVSY EPGSYIVVDGIKFELKQFHFHAPSEHKLKGQHYPFEAHFVHADKHGNLA VIGVFFKEGRENPILEKIWKVMPENAGEEVKLAHKINAEDLLPKDRDYY RYSGSLTTPPCSECVRWIVMEEEMEMSKEQIEKFRKIMGGDTNRPVQPL CARMIMEK (DNA) SEQIDNO:4 ATGAAACAACAGAAAAGACTGTATGCACGCCTGCTTACATTACTGTTTG CTCTTATTTTTCTTTTACCGCATTCAGCAGCGGCTGCCGGCGGAGGATG GAGCTATCATGGCGAACATGGACCTGAACATTGGGGTGACCTGAAAGAC GAATATATTATGTGCAAAATCGGCAAAAATCAATCACCGGTTGATATTA ACAGAATCGTGGATGCAAAACTTAAACCGATCAAAATCGAATATCGCGC AGGAGCGACAAAAGTCCTGAACAACGGCCATACAATCAAAGTTTCTTAT GAACCGGGATCATATATTGTTGTGGATGGCATCAAATTTGAATTAAAAC AATTTCATTTTCATGCACCGAGCGAACATAAACTGAAAGGACAGCATTA TCCGTTTGAAGCTCATTTTGTTCATGCCGATAAACATGGCAATCTGGCT GTCATCGGAGTTTTCTTTAAAGAAGGCAGAGAAAACCCGATTCTTGAAA AAATCTGGAAAGTGATGCCGGAAAATGCCGGCGAAGAAGTCAAATTAGC ACATAAAATCAACGCGGAAGATTTACTGCCGAAAGATAGAGATTATTAT CGCTATTCAGGAAGCCTGACAACACCGCCGTGCAGCGAATGCGTGAGAT GGATCGTCATGGAAGAAGAAATGGAAATGTCTAAAGAACAGATCGAAAA ATTTCGCAAAATCATGGGAGGCGATACGAACCGTCCTGTGCAGCCGTTG TGTGCGAGAATGATTATGGAAAAATAA

[0090] SEQ ID NO: 5 and SEQ ID NO: 6

[0091] SEQ name: SPamyL-PmaCA-CA3mut2

[0092] LENGTH: 253 for PRT; 762 for DNA

[0093] TYPE: PRT; DNA

[0094] ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; PmaCA-CA3mut2 modified from Persephonella marina.

TABLE-US-00008 (PRT) SEQIDNO:5 MKQQKRLYARLLTLLFALIFLLPHSAAAAGGGWSYHGEHGPEHWG DLKDEYIMCKIGKNQSPVDINRIVDCKLKPIKIEYRAGATKVLN NGHTIKVSYEPGSYIVVDGIKFELKQFHFHAPSEHKLKGQHYPFE AHFVHADKHGNLAVIGVFFKEGRENPILEKIWKVMPENAGEEVKL AHKINAEDLLPKDRDYYRYSGSLTTPPCSEGVRWIVMEEEMEMSK EQIEKFRKIMGGDTNRPVQPLNARMIMEK (DNA) SEQIDNO:6 ATGAAACAACAGAAAAGACTGTATGCACGCCTGCTTACATTACTG TTTGCTCTTATTTTTCTTTTACCGCATTCAGCAGCGGCTGCCGG CGGAGGATGGAGCTATCATGGCGAACATGGACCTGAACATTGGGG TGACCTGAAAGACGAATATATTATGTGCAAAATCGGCAAAAATCA ATCACCGGTTGATATTAACAGAATCGTGGATTGTAAACTTAAACC GATCAAAATCGAATATCGCGCAGGAGCGACAAAAGTCCTGAACAA CGGCCATACAATCAAAGTTTCTTATGAACCGGGATCATATATTGT TGTGGATGGCATCAAATTTGAATTAAAACAATTTCATTTTCATGC ACCGAGCGAACATAAACTGAAAGGACAGCATTATCCGTTTGAAGC TCATTTTGTTCATGCCGATAAACATGGCAATCTGGCTGTCATCGG AGTTTTCTTTAAAGAAGGCAGAGAAAACCCGATTCTTGAAAAAAT CTGGAAAGTGATGCCGGAAAATGCCGGCGAAGAAGTCAAATTAGC ACATAAAATCAACGCGGAAGATTTACTGCCGAAAGATAGAGATTA TTATCGCTATTCAGGAAGCCTGACAACACCGCCGTGCAGCGAAGG CGTGAGATGGATCGTCATGGAAGAAGAAATGGAAATGTCTAAAGA ACAGATCGAAAAATTTCGCAAAATCATGGGAGGCGATACGAACCG TCCTGTGCAGCCGTTGAATGCGAGAATGATTATGGAAAAATAA

[0095] SEQ ID NO: 7 and SEQ ID NO: 8

[0096] SEQ name: SPamyL-PmaCA-CA3mut3

[0097] LENGTH: 253 for PRT; 762 for DNA

[0098] TYPE: PRT; DNA

[0099] ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; PmaCA-CA3mut3 modified from Persephonella marina.

TABLE-US-00009 (PRT) SEQIDNO:7 MKQQKRLYARLLTLLFALIFLLPHSAAAAGGGWSYHGEHGPEHWG DLKDEYIMCKIGKNQSPVDINRIVDAKLKPIKIEYRAGATKVLN NGHTIKVSYEPGSYIVVDGIKFELKQFHFHAPSEHKLKGQHYPFE AHFVHADKHGNLAVIGVFFKEGRENPILEKIWKVMPENAGEEVKL AHKINAEDLLPKDRDYYRYCGSLTTPPCSEGVRWIVMEEEMEMSK EQIEKFRKIMGGDTNRPVQPLCARMIMEK (DNA) SEQIDNO:8 ATGAAACAACAGAAAAGACTGTATGCACGCCTGCTTACATTACTG TTTGCTCTTATTTTTCTTTTACCGCATTCAGCAGCGGCTGCCGG CGGAGGATGGAGCTATCATGGCGAACATGGACCTGAACATTGGGG TGACCTGAAAGACGAATATATTATGTGCAAAATCGGCAAAAATCA ATCACCGGTTGATATTAACAGAATCGTGGATGCAAAACTTAAACC GATCAAAATCGAATATCGCGCAGGAGCGACAAAAGTCCTGAACAA CGGCCATACAATCAAAGTTTCTTATGAACCGGGATCATATATTGT TGTGGATGGCATCAAATTTGAATTAAAACAATTTCATTTTCATGC ACCGAGCGAACATAAACTGAAAGGACAGCATTATCCGTTTGAAGC TCATTTTGTTCATGCCGATAAACATGGCAATCTGGCTGTCATCGG AGTTTTCTTTAAAGAAGGCAGAGAAAACCCGATTCTTGAAAAAAT CTGGAAAGTGATGCCGGAAAATGCCGGCGAAGAAGTCAAATTAGC ACATAAAATCAACGCGGAAGATTTACTGCCGAAAGATAGAGATTA TTATCGCTATTGTGGAAGCCTGACAACACCGCCGTGCAGCGAAGG CGTGAGATGGATCGTCATGGAAGAAGAAATGGAAATGTCTAAAGA ACAGATCGAAAAATTTCGCAAAATCATGGGAGGCGATACGAACCG TCCTGTGCAGCCGTTGTGTGCGAGAATGATTATGGAAAAATAA

[0100] SEQ ID NO: 9 and SEQ ID NO: 10

[0101] SEQ name: SPamyL-PmaCA-CA3mut23

[0102] LENGTH: 253 for PRT; 762 for DNA

[0103] TYPE: PRT; DNA

[0104] ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; PmaCA-CA3mut23 modified from Persephonella marina.

TABLE-US-00010 (PRT) SEQIDNO:9 MKQQKRLYARLLTLLFALIFLLPHSAAAAGGGWSYHGEHGPEHWG DLKDEYIMCKIGKNQSPVDINRIVDCKLKPIKIEYRAGATKVLN NGHTIKVSYEPGSYIVVDGIKFELKQFHFHAPSEHKLKGQHYPFE AHFVHADKHGNLAVIGVFFKEGRENPILEKIWKVMPENAGEEVKL AHKINAEDLLPKDRDYYRYCGSLTTPPCSEGVRWIVMEEEMEMSK EQIEKFRKIMGGDTNRPVQPLNCRMIMEK (DNA) SEQIDNO:10 ATGAAACAACAGAAAAGACTGTATGCACGCCTGCTTACATTACTG TTTGCTCTTATTTTTCTTTTACCGCATTCAGCAGCGGCTGCCGG CGGAGGATGGAGCTATCATGGCGAACATGGACCTGAACATTGGGG TGACCTGAAAGACGAATATATTATGTGCAAAATCGGCAAAAATCA ATCACCGGTTGATATTAACAGAATCGTGGATTGTAAACTTAAACC GATCAAAATCGAATATCGCGCAGGAGCGACAAAAGTCCTGAACAA CGGCCATACAATCAAAGTTTCTTATGAACCGGGATCATATATTGT TGTGGATGGCATCAAATTTGAATTAAAACAATTTCATTTTCATGC ACCGAGCGAACATAAACTGAAAGGACAGCATTATCCGTTTGAAGC TCATTTTGTTCATGCCGATAAACATGGCAATCTGGCTGTCATCGG AGTTTTCTTTAAAGAAGGCAGAGAAAACCCGATTCTTGAAAAAAT CTGGAAAGTGATGCCGGAAAATGCCGGCGAAGAAGTCAAATTAGC ACATAAAATCAACGCGGAAGATTTACTGCCGAAAGATAGAGATTA TTATCGCTATTGTGGAAGCCTGACAACACCGCCGTGCAGCGAAGG CGTGAGATGGATCGTCATGGAAGAAGAAATGGAAATGTCTAAAGA ACAGATCGAAAAATTTCGCAAAATCATGGGAGGCGATACGAACCG TCCTGTGCAGCCGTTGTGTGCGAGAATGATTATGGAAAAATAA

[0105] SEQ ID NO: 11 and SEQ ID NO: 12

[0106] SEQ name: SPamyL-LOGACA-CA4

[0107] LENGTH: 255 for PRT; 768 for DNA

[0108] ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; LOGACA-CA4 from deep sea thermal vent.

TABLE-US-00011 (PRT) SEQIDNO:11 MKQQKRLYARLLTLLFALIFLLPHSAAAAGGVGHWSYHGETGPQH WGDLKNEYIMCKIGKNQSPVDISRIVEAELEKIKINYSSGGSSI TNNGHTIKVSYEPGSYIIVDGIRFELKQFHFHAPSEHTIKGKSYP FEAHFVHADKDGNLAVIGVIFKEGKKNPIIEKIWENLPEAGKTIK LAHKINAYDLLPKKKKYYRYSGSLTTPPCSEGVRWIVMEEEMELS KEQIEKFRKLMGGDTNRPVQPLNARMIMEMD (DNA) SEQIDNO:12 ATGAAACAACAGAAAAGACTGTATGCACGCCTGCTTACATTACTG TTTGCTCTTATTTTTCTTTTACCGCATTCAGCAGCGGCTGCCGG CGGAGTTGGACATTGGTCTTATCATGGCGAAACAGGACCGCAACA TTGGGGCGATCTGAAAAACGAATACATCATGTGCAAAATCGGCAA AAACCAGTCACCGGTGGATATTAGCAGAATCGTCGAAGCTGAACT TGAAAAAATCAAAATCAACTATTCAAGCGGCGGATCTTCAATCAC AAACAACGGACATACAATCAAAGTTTCTTATGAACCGGGATCATA TATTATCGTGGATGGCATTCGCTTTGAATTAAAACAATTTCATTT TCATGCCCCGAGCGAACATACAATCAAAGGCAAATCTTATCCGTT TGAAGCACATTTTGTCCATGCGGATAAAGATGGCAATCTGGCAGT TATTGGAGTGATCTTTAAAGAAGGCAAGAAAAATCCGATCATCGA AAAAATTTGGGAAAACTTACCGGAAGCGGGCAAAACAATCAAACT GGCTCATAAAATCAACGCCTATGATCTGCTTCCGAAAAAGAAAAA ATACTACAGATACAGCGGATCTCTTACAACACCGCCGTGTTCAGA AGGCGTCCGCTGGATTGTTATGGAAGAAGAAATGGAACTTAGCAA AGAACAAATCGAAAAATTTAGAAAACTGATGGGCGGAGATACAAA TAGACCGGTTCAGCCGTTAAACGCTCGCATGATTATGGAAATGGA TTAA

[0109] SEQ ID NO: 13 and SEQ ID NO: 14

[0110] SEQ name: SPamyL-LOGACA-CA4mut2

[0111] LENGTH: 255 for PRT; 768 for DNA

[0112] TYPE: PRT; DNA

[0113] ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; LOGACA-CA4mut2 modified from deep sea thermal vent.

TABLE-US-00012 (PRT) SEQIDNO:13 MKQQKRLYARLLTLLFALIFLLPHSAAAAGGVGHWSYHGETGPQH WGDLKNEYIMCKIGKNQSPVDISRIVECELEKIKINYSSGGSSI TNNGHTIKVSYEPGSYIIVDGIRFELKQFHFHAPSEHTIKGKSYP FEAHFVHADKDGNLAVIGVIFKEGKKNPIIEKIWENLPEAGKTIK LAHKINAYDLLPKKKKYYRYSGSLTTPPCSEGVRWIVMEEEMELS KEQIEKFRKLMGGDTNRPVQPLNARMIMEMD (DNA) SEQIDNO:14 ATGAAACAACAGAAAAGACTGTATGCACGCCTGCTTACATTACTG TTTGCTCTTATTTTTCTTTTACCGCATTCAGCAGCGGCTGCCGG CGGAGTTGGACATTGGTCTTATCATGGCGAAACAGGACCGCAACA TTGGGGCGATCTGAAAAACGAATACATCATGTGCAAAATCGGCAA AAACCAGTCACCGGTGGATATTAGCAGAATCGTCGAATGTGAACT TGAAAAAATCAAAATCAACTATTCAAGCGGCGGATCTTCAATCAC AAACAACGGACATACAATCAAAGTTTCTTATGAACCGGGATCATA TATTATCGTGGATGGCATTCGCTTTGAATTAAAACAATTTCATTT TCATGCCCCGAGCGAACATACAATCAAAGGCAAATCTTATCCGTT TGAAGCACATTTTGTCCATGCGGATAAAGATGGCAATCTGGCAGT TATTGGAGTGATCTTTAAAGAAGGCAAGAAAAATCCGATCATCGA AAAAATTTGGGAAAACTTACCGGAAGCGGGCAAAACAATCAAACT GGCTCATAAAATCAACGCCTATGATCTGCTTCCGAAAAAGAAAAA ATACTACAGATACAGCGGATCTCTTACAACACCGCCGTGTTCAGA AGGCGTCCGCTGGATTGTTATGGAAGAAGAAATGGAACTTAGCAA AGAACAAATCGAAAAATTTAGAAAACTGATGGGCGGAGATACAAA TAGACCGGTTCAGCCGTTAAACGCTCGCATGATTATGGAAATGGA TTAA

[0114] SEQ ID NO: 15 and SEQ ID NO: 16

[0115] SEQ name: SPamyL-LOGACA-CA4mut3

[0116] LENGTH: 255 for PRT; 768 for DNA

[0117] TYPE: PRT; DNA

[0118] ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; LOGACA-CA4mut3 modified from deep sea thermal vent.

TABLE-US-00013 (PRT) SEQIDNO:15 MKQQKRLYARLLTLLFALIFLLPHSAAAAGGVGHWSYHGETGPQH WGDLKNEYIMCKIGKNQSPVDISRIVEAELEKIKINYSSGGSSI TNNGHTIKVSYEPGSYIIVDGIRFELKQFHFHAPSEHTIKGKSYP FEAHFVHADKDGNLAVIGVIFKEGKKNPIIEKIWENLPEAGKTIK LAHKINAYDLLPKKKKYYRYCGSLTTPPCSEGVRWIVMEEEMELS KEQIEKFRKLMGGDTNRPVQPLNCRMIMEMD (DNA) SEQIDNO:16 ATGAAACAACAGAAAAGACTGTATGCACGCCTGCTTACATTACTG TTTGCTCTTATTTTTCTTTTACCGCATTCAGCAGCGGCTGCCGG CGGAGTTGGACATTGGTCTTATCATGGCGAAACAGGACCGCAACA TTGGGGCGATCTGAAAAACGAATACATCATGTGCAAAATCGGCAA AAACCAGTCACCGGTGGATATTAGCAGAATCGTCGAAGCTGAACT TGAAAAAATCAAAATCAACTATTCAAGCGGCGGATCTTCAATCAC AAACAACGGACATACAATCAAAGTTTCTTATGAACCGGGATCATA TATTATCGTGGATGGCATTCGCTTTGAATTAAAACAATTTCATTT TCATGCCCCGAGCGAACATACAATCAAAGGCAAATCTTATCCGTT TGAAGCACATTTTGTCCATGCGGATAAAGATGGCAATCTGGCAGT TATTGGAGTGATCTTTAAAGAAGGCAAGAAAAATCCGATCATCGA AAAAATTTGGGAAAACTTACCGGAAGCGGGCAAAACAATCAAACT GGCTCATAAAATCAACGCCTATGATCTGCTTCCGAAAAAGAAAAA ATACTACAGATACTGCGGATCTCTTACAACACCGCCGTGTTCAGA AGGCGTCCGCTGGATTGTTATGGAAGAAGAAATGGAACTTAGCAA AGAACAAATCGAAAAATTTAGAAAACTGATGGGCGGAGATACAAA TAGACCGGTTCAGCCGTTAAACTGTCGCATGATTATGGAAATGGA TTAA

[0119] SEQ ID NO: 17 and SEQ ID NO: 18

[0120] SEQ name: SPamyL-LOGACA-CA4mut23

[0121] LENGTH: 255 for PRT; 768 for DNA

[0122] TYPE: PRT; DNA

[0123] ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; LOGACA-CA4mut23 modified from deep sea thermal vent.

TABLE-US-00014 (PRT) SEQIDNO:17 MKQQKRLYARLLTLLFALIFLLPHSAAAAGGVGHWSYHGETGPQH WGDLKNEYIMCKIGKNQSPVDISRIVECELEKIKINYSSGGSSI TNNGHTIKVSYEPGSYIIVDGIRFELKQFHFHAPSEHTIKGKSYP FEAHFVHADKDGNLAVIGVIFKEGKKNPIIEKIWENLPEAGKTIK LAHKINAYDLLPKKKKYYRYCGSLTTPPCSEGVRWIVMEEEMELS KEQIEKFRKLMGGDTNRPVQPLNCRMIMEMD (DNA) SEQIDNO:18 ATGAAACAACAGAAAAGACTGTATGCACGCCTGCTTACATTACTG TTTGCTCTTATTTTTCTTTTACCGCATTCAGCAGCGGCTGCCGG CGGAGTTGGACATTGGTCTTATCATGGCGAAACAGGACCGCAACA TTGGGGCGATCTGAAAAACGAATACATCATGTGCAAAATCGGCAA AAACCAGTCACCGGTGGATATTAGCAGAATCGTCGAATGTGAACT TGAAAAAATCAAAATCAACTATTCAAGCGGCGGATCTTCAATCAC AAACAACGGACATACAATCAAAGTTTCTTATGAACCGGGATCATA TATTATCGTGGATGGCATTCGCTTTGAATTAAAACAATTTCATTT TCATGCCCCGAGCGAACATACAATCAAAGGCAAATCTTATCCGTT TGAAGCACATTTTGTCCATGCGGATAAAGATGGCAATCTGGCAGT TATTGGAGTGATCTTTAAAGAAGGCAAGAAAAATCCGATCATCGA AAAAATTTGGGAAAACTTACCGGAAGCGGGCAAAACAATCAAACT GGCTCATAAAATCAACGCCTATGATCTGCTTCCGAAAAAGAAAAA ATACTACAGATACTGCGGATCTCTTACAACACCGCCGTGTTCAGA AGGCGTCCGCTGGATTGTTATGGAAGAAGAAATGGAACTTAGCAA AGAACAAATCGAAAAATTTAGAAAACTGATGGGCGGAGATACAAA TAGACCGGTTCAGCCGTTAAACTGTCGCATGATTATGGAAATGGA TTAA

[0124] SEQ ID NO: 19 and SEQ ID NO: 20

[0125] SEQ name: SPamyL-SspCA-CA5

[0126] LENGTH: 255 for PRT; 768 for DNA

[0127] TYPE: PRT; DNA

[0128] ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; SspCA-CA5 from Sulfurihydrogenibium sp. strain YO3AOP1.

TABLE-US-00015 (PRT) SEQIDNO:19 MKQQKRLYARLLTLLFALIFLLPHSAAAAEHEWSYEGEKGPEHWA QLKPEFFWCKLKNQSPINIDKKYKVKANLPKLNLYYKTAKESEV VNNGHTIQINIKEDNTLNYLGEKYQLKQFHFHTPSEHTIEKKSYP LEIHFVHKTEDGKILVVGVMAKLGKTNKELDKILNVAPAEEGEKI LDKNLNLNNLIPKDKRYMTYSGSLTTPPCTEGVRWIVLKKPISIS KQQLEKLKSVMVNPNNRPVQEINSRWIIEGF (DNA) SEQIDNO:20 ATGAAACAACAGAAAAGACTGTATGCACGCCTGCTTACATTACTG TTTGCTCTTATTTTTCTTTTACCGCATTCAGCAGCGGCTGCCGA ACATGAATGGTCTTATGAAGGCGAAAAAGGACCGGAACATTGGGC ACAACTGAAACCGGAATTTTTCTGGTGCAAACTTAAAAACCAGTC ACCGATCAACATCGATAAAAAATACAAAGTTAAAGCTAACCTGCC GAAACTGAACCTTTACTACAAAACAGCCAAAGAATCAGAAGTTGT GAATAACGGACATACAATCCAAATCAACATCAAAGAAGATAACAC ACTTAACTACCTGGGCGAAAAATACCAACTGAAACAGTTTCATTT TCATACACCGAGCGAACATACAATCGAGAAAAAATCATACCCGCT TGAAATCCATTTTGTCCATAAAACAGAAGATGGCAAAATCCTTGT CGTTGGAGTTATGGCTAAACTGGGCAAAACAAACAAAGAATTAGA TAAAATTCTGAACGTGGCACCGGCGGAAGAAGGAGAAAAAATCTT AGATAAAAACCTGAACCTGAACAACCTGATCCCGAAAGATAAAAG ATACATGACATACTCAGGAAGCCTTACAACACCGCCGTGTACAGA AGGCGTTCGCTGGATCGTGCTGAAAAAACCGATCTCTATTTCAAA ACAACAGCTGGAAAAACTTAAATCAGTGATGGTCAATCCGAATAA CAGACCGGTCCAGGAAATTAACAGCCGCTGGATTATCGAAGGCTT TTAA

[0129] SEQ ID NO: 21 and SEQ ID NO: 22

[0130] SEQ name: SPamyL-SspCA-CA5mut2

[0131] LENGTH: 255 for PRT; 768 for DNA

[0132] TYPE: PRT; DNA

[0133] ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; SspCA-CA5mut2 modified from Sulfurihydrogenibium sp. strain YO3AOP1.

TABLE-US-00016 (PRT) SEQIDNO:21 MKQQKRLYARLLTLLFALIFLLPHSAAAAEHEWSYEGEKGPEHWA QLKPEFFWCKLKNQSPINIDKKYKVKCNLPKLNLYYKTAKESEV VNNGHTIQINIKEDNTLNYLGEKYQLKQFHFHTPSEHTIEKKSYP LEIHFVHKTEDGKILVVGVMAKLGKTNKELDKILNVAPAEEGEKI LDKNLNLNNLIPKDKRYMTYSGSLTTPPCTEGVRWIVLKKPISIS KQQLEKLKSVMVNPNNRPVQEINSRWIIEGF (DNA) SEQIDNO:22 ATGAAACAACAGAAAAGACTGTATGCACGCCTGCTTACATTACTG TTTGCTCTTATTTTTCTTTTACCGCATTCAGCAGCGGCTGCCGA ACATGAATGGTCTTATGAAGGCGAAAAAGGACCGGAACATTGGGC ACAACTGAAACCGGAATTTTTCTGGTGCAAACTTAAAAACCAGTC ACCGATCAACATCGATAAAAAATACAAAGTTAAATGTAACCTGCC GAAACTGAACCTTTACTACAAAACAGCCAAAGAATCAGAAGTTGT GAATAACGGACATACAATCCAAATCAACATCAAAGAAGATAACAC ACTTAACTACCTGGGCGAAAAATACCAACTGAAACAGTTTCATTT TCATACACCGAGCGAACATACAATCGAGAAAAAATCATACCCGCT TGAAATCCATTTTGTCCATAAAACAGAAGATGGCAAAATCCTTGT CGTTGGAGTTATGGCTAAACTGGGCAAAACAAACAAAGAATTAGA TAAAATTCTGAACGTGGCACCGGCGGAAGAAGGAGAAAAAATCTT AGATAAAAACCTGAACCTGAACAACCTGATCCCGAAAGATAAAAG ATACATGACATACTCAGGAAGCCTTACAACACCGCCGTGTACAGA AGGCGTTCGCTGGATCGTGCTGAAAAAACCGATCTCTATTTCAAA ACAACAGCTGGAAAAACTTAAATCAGTGATGGTCAATCCGAATAA CAGACCGGTCCAGGAAATTAACAGCCGCTGGATTATCGAAGGCTT TTAA

[0134] SEQ ID NO: 23 and SEQ ID NO: 24

[0135] SEQ name: SPamyL-SspCA-CA5mut3

[0136] LENGTH: 255 for PRT; 768 for DNA

[0137] TYPE: PRT; DNA

[0138] ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; SspCA-CA5mut3 modified from Sulfurihydrogenibium sp. strain YO3AOP1.

TABLE-US-00017 (PRT) SEQIDNO:23 MKQQKRLYARLLTLLFALIFLLPHSAAAAEHEWSYEGEKGPEHWA QLKPEFFWCKLKNQSPINIDKKYKVKANLPKLNLYYKTAKESEV VNNGHTIQINIKEDNTLNYLGEKYQLKQFHFHTPSEHTIEKKSYP LEIHFVHKTEDGKILVVGVMAKLGKTNKELDKILNVAPAEEGEKI LDKNLNLNNLIPKDKRYMTYCGSLTTPPCTEGVRWIVLKKPISIS KQQLEKLKSVMVNPNNRPVQEINCRWIIEGF (DNA) SEQIDNO:24 ATGAAACAACAGAAAAGACTGTATGCACGCCTGCTTACATTACTG TTTGCTCTTATTTTTCTTTTACCGCATTCAGCAGCGGCTGCCGA ACATGAATGGTCTTATGAAGGCGAAAAAGGACCGGAACATTGGGC ACAACTGAAACCGGAATTTTTCTGGTGCAAACTTAAAAACCAGTC ACCGATCAACATCGATAAAAAATACAAAGTTAAAGCTAACCTGCC GAAACTGAACCTTTACTACAAAACAGCCAAAGAATCAGAAGTTGT GAATAACGGACATACAATCCAAATCAACATCAAAGAAGATAACAC ACTTAACTACCTGGGCGAAAAATACCAACTGAAACAGTTTCATTT TCATACACCGAGCGAACATACAATCGAGAAAAAATCATACCCGCT TGAAATCCATTTTGTCCATAAAACAGAAGATGGCAAAATCCTTGT CGTTGGAGTTATGGCTAAACTGGGCAAAACAAACAAAGAATTAGA TAAAATTCTGAACGTGGCACCGGCGGAAGAAGGAGAAAAAATCTT AGATAAAAACCTGAACCTGAACAACCTGATCCCGAAAGATAAAAG ATACATGACATACTGCGGAAGCCTTACAACACCGCCGTGTACAGA AGGCGTTCGCTGGATCGTGCTGAAAAAACCGATCTCTATTTCAAA ACAACAGCTGGAAAAACTTAAATCAGTGATGGTCAATCCGAATAA CAGACCGGTCCAGGAAATTAACTGTCGCTGGATTATCGAAGGCTT TTAA

[0139] SEQ ID NO: 25 and SEQ ID NO: 26

[0140] SEQ name: SPamyL-SspCA-CA5mut23

[0141] LENGTH: 255 for PRT; 768 for DNA

[0142] TYPE: PRT; DNA

[0143] ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; SspCA-CA5mut23 modified from Sulfurihydrogenibium sp. strain YO3AOP1.

TABLE-US-00018 (PRT) SEQIDNO:25 MKQQKRLYARLLTLLFALIFLLPHSAAAAEHEWSYEGEKGPEHWA QLKPEFFWCKLKNQSPINIDKKYKVKCNLPKLNLYYKTAKESEV VNNGHTIQINIKEDNTLNYLGEKYQLKQFHFHTPSEHTIEKKSYP LEIHFVHKTEDGKILVVGVMAKLGKTNKELDKILNVAPAEEGEKI LDKNLNLNNLIPKDKRYMTYCGSLTTPPCTEGVRWIVLKKPISIS KQQLEKLKSVMVNPNNRPVQEINCRWIIEGF (DNA) SEQIDNO:26 ATGAAACAACAGAAAAGACTGTATGCACGCCTGCTTACATTACTG TTTGCTCTTATTTTTCTTTTACCGCATTCAGCAGCGGCTGCCGA ACATGAATGGTCTTATGAAGGCGAAAAAGGACCGGAACATTGGGC ACAACTGAAACCGGAATTTTTCTGGTGCAAACTTAAAAACCAGTC ACCGATCAACATCGATAAAAAATACAAAGTTAAATGTAACCTGCC GAAACTGAACCTTTACTACAAAACAGCCAAAGAATCAGAAGTTGT GAATAACGGACATACAATCCAAATCAACATCAAAGAAGATAACAC ACTTAACTACCTGGGCGAAAAATACCAACTGAAACAGTTTCATTT TCATACACCGAGCGAACATACAATCGAGAAAAAATCATACCCGCT TGAAATCCATTTTGTCCATAAAACAGAAGATGGCAAAATCCTTGT CGTTGGAGTTATGGCTAAACTGGGCAAAACAAACAAAGAATTAGA TAAAATTCTGAACGTGGCACCGGCGGAAGAAGGAGAAAAAATCTT AGATAAAAACCTGAACCTGAACAACCTGATCCCGAAAGATAAAAG ATACATGACATACTGCGGAAGCCTTACAACACCGCCGTGTACAGA AGGCGTTCGCTGGATCGTGCTGAAAAAACCGATCTCTATTTCAAA ACAACAGCTGGAAAAACTTAAATCAGTGATGGTCAATCCGAATAA CAGACCGGTCCAGGAAATTAACTGTCGCTGGATTATCGAAGGCTT TTAA

[0144] SEQ ID NO: 27 and SEQ ID NO: 28

[0145] SEQ name: SPamyL-SazCA-CA6FL

[0146] LENGTH: 266 for PRT; 801 for DNA

[0147] TYPE: PRT; DNA

[0148] ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; SazCA-CA6FL from Sulfurihydrogenibium azorense

TABLE-US-00019 (PRT) SEQIDNO:27 MKQQKRLYARLLTLLFALIFLLPHSAAAAGEHAILQKNAEVHHWS YEGENGPENWAKLNPEYFWCNLKNQSPVDISDNYKVHAKLEKLH INYNKAVNPEIVNNGHTIQVNVLEDFKLNIKGKEYHLKQFHFHAP SEHTVNGKYYPLEMHLVHKDKDGNIAVIGVFFKEGKANPELDKVF KNALKEEGSKVFDGSININALLPPVKNYYTYSGSLTTPPCTEGVL WIVLKQPITASKQQIELFKSIMKHNNNRPTQPINSRYILESN (DNA) Inanembodiment,alsoreferredtoas: >2_Gene6-pH43-SPamyL-fullSazCA SEQIDNO:28 ATGAAACAACAGAAAAGACTGTATGCACGCCTGCTTACATTACTG TTTGCTCTTATTTTTCTTTTACCGCATTCAGCAGCGGCTGCCGG CGAACATGCAATTCTGCAGAAAAATGCGGAAGTCCATCATTGGAG CTATGAAGGCGAAAACGGACCGGAAAATTGGGCCAAACTGAACCC GGAATACTTTTGGTGCAACCTTAAAAACCAGTCTCCGGTCGATAT TTCAGATAACTACAAAGTTCATGCCAAACTGGAAAAACTGCATAT CAACTACAACAAAGCAGTTAACCCGGAAATTGTGAATAACGGACA TACAATCCAAGTTAACGTGTTAGAAGATTTTAAACTGAACATCAA AGGCAAAGAATACCATCTTAAACAGTTTCATTTTCATGCTCCGTC TGAACATACAGTGAACGGCAAATATTATCCGCTTGAAATGCATCT GGTCCATAAAGATAAAGATGGCAACATTGCAGTCATCGGAGTTTT CTTTAAAGAAGGCAAAGCGAACCCGGAACTTGATAAAGTTTTTAA AAACGCTCTGAAAGAAGAAGGAAGCAAAGTGTTTGATGGCTCTAT TAACATCAATGCGCTGCTTCCGCCGGTTAAAAACTACTACACATA CTCAGGAAGCTTAACAACACCGCCGTGTACAGAAGGCGTGCTGTG GATTGTCCTTAAACAACCGATCACAGCTTCTAAACAACAGATTGA ACTGTTTAAATCAATCATGAAACATAACAACAATAGACCGACACA GCCGATTAACTCACGCTATATCCTGGAAAGCAATTAA

[0149] SEQ ID NO: 29 and SEQ ID NO: 30

[0150] SEQ name: SPamyL-SazCA-CA6FLmut2

[0151] LENGTH: 266 for PRT; 801 for DNA

[0152] TYPE: PRT; DNA

[0153] ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; SazCA-CA6FLmut2 modified from Sulfurihydrogenibium azorense

TABLE-US-00020 (PRT) SEQIDNO:29 MKQQKRLYARLLTLLFALIFLLPHSAAAAGEHAILQKNAEVHHWS YEGENGPENWAKLNPEYFWCNLKNQSPVDISDNYKVHCKLEKLH INYNKAVNPEIVNNGHTIQVNVLEDFKLNIKGKEYHLKQFHFHAP SEHTVNGKYYPLEMHLVHKDKDGNIAVIGVFFKEGKANPELDKVF KNALKEEGSKVFDGSININALLPPVKNYYTYSGSLTTPPCTEGVL WIVLKQPITASKQQIELFKSIMKHNNNRPTQPINSRYILESN (DNA) SEQIDNO:30 ATGAAACAACAGAAAAGACTGTATGCACGCCTGCTTACATTACTG TTTGCTCTTATTTTTCTTTTACCGCATTCAGCAGCGGCTGCCGG CGAACATGCAATTCTGCAGAAAAATGCGGAAGTCCATCATTGGAG CTATGAAGGCGAAAACGGACCGGAAAATTGGGCCAAACTGAACCC GGAATACTTTTGGTGCAACCTTAAAAACCAGTCTCCGGTCGATAT TTCAGATAACTACAAAGTTCATTGTAAACTGGAAAAACTGCATAT CAACTACAACAAAGCAGTTAACCCGGAAATTGTGAATAACGGACA TACAATCCAAGTTAACGTGTTAGAAGATTTTAAACTGAACATCAA AGGCAAAGAATACCATCTTAAACAGTTTCATTTTCATGCTCCGTC TGAACATACAGTGAACGGCAAATATTATCCGCTTGAAATGCATCT GGTCCATAAAGATAAAGATGGCAACATTGCAGTCATCGGAGTTTT CTTTAAAGAAGGCAAAGCGAACCCGGAACTTGATAAAGTTTTTAA AAACGCTCTGAAAGAAGAAGGAAGCAAAGTGTTTGATGGCTCTAT TAACATCAATGCGCTGCTTCCGCCGGTTAAAAACTACTACACATA CTCAGGAAGCTTAACAACACCGCCGTGTACAGAAGGCGTGCTGTG GATTGTCCTTAAACAACCGATCACAGCTTCTAAACAACAGATTGA ACTGTTTAAATCAATCATGAAACATAACAACAATAGACCGACACA GCCGATTAACTCACGCTATATCCTGGAAAGCAATTAA

[0154] SEQ ID NO: 31 and SEQ ID NO: 32

[0155] SEQ name: SPamyL-SazCA-CA6FLmut3

[0156] LENGTH: 266 for PRT; 801 for DNA

[0157] TYPE: PRT; DNA

[0158] ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; SazCA-CA6FLmut3 modified from Sulfurihydrogenibium azorense

TABLE-US-00021 (PRT) SEQIDNO:31 MKQQKRLYARLLTLLFALIFLLPHSAAAAGEHAILQKNAEVHHWS YEGENGPENWAKLNPEYFWCNLKNQSPVDISDNYKVHAKLEKLH INYNKAVNPEIVNNGHTIQVNVLEDFKLNIKGKEYHLKQFHFHAP SEHTVNGKYYPLEMHLVHKDKDGNIAVIGVFFKEGKANPELDKVF KNALKEEGSKVFDGSININALLPPVKNYYTYCGSLTTPPCTEGVL WIVLKQPITASKQQIELFKSIMKHNNNRPTQPINCRYILESN (DNA) SEQIDNO:32 ATGAAACAACAGAAAAGACTGTATGCACGCCTGCTTACATTACTG TTTGCTCTTATTTTTCTTTTACCGCATTCAGCAGCGGCTGCCGG CGAACATGCAATTCTGCAGAAAAATGCGGAAGTCCATCATTGGAG CTATGAAGGCGAAAACGGACCGGAAAATTGGGCCAAACTGAACCC GGAATACTTTTGGTGCAACCTTAAAAACCAGTCTCCGGTCGATAT TTCAGATAACTACAAAGTTCATGCCAAACTGGAAAAACTGCATAT CAACTACAACAAAGCAGTTAACCCGGAAATTGTGAATAACGGACA TACAATCCAAGTTAACGTGTTAGAAGATTTTAAACTGAACATCAA AGGCAAAGAATACCATCTTAAACAGTTTCATTTTCATGCTCCGTC TGAACATACAGTGAACGGCAAATATTATCCGCTTGAAATGCATCT GGTCCATAAAGATAAAGATGGCAACATTGCAGTCATCGGAGTTTT CTTTAAAGAAGGCAAAGCGAACCCGGAACTTGATAAAGTTTTTAA AAACGCTCTGAAAGAAGAAGGAAGCAAAGTGTTTGATGGCTCTAT TAACATCAATGCGCTGCTTCCGCCGGTTAAAAACTACTACACATA CTGCGGAAGCTTAACAACACCGCCGTGTACAGAAGGCGTGCTGTG GATTGTCCTTAAACAACCGATCACAGCTTCTAAACAACAGATTGA ACTGTTTAAATCAATCATGAAACATAACAACAATAGACCGACACA GCCGATTAACTGTCGCTATATCCTGGAAAGCAATTAA

[0159] SEQ ID NO: 33 and SEQ ID NO: 34

[0160] SEQ name: SPamyL-SazCA-CA6FLmut23

[0161] LENGTH: 266 for PRT; 801 for DNA

[0162] TYPE: PRT; DNA

[0163] ORGANISM: Signal peptide SPamyL from Bacillus licheniformis; SazCA-CA6FLmut23 modified from Sulfurihydrogenibium azorense

TABLE-US-00022 (PRT) SEQIDNO:33 MKQQKRLYARLLTLLFALIFLLPHSAAAAGEHAILQKNAEVHHWS YEGENGPENWAKLNPEYFWCNLKNQSPVDISDNYKVHCKLEKLH INYNKAVNPEIVNNGHTIQVNVLEDFKLNIKGKEYHLKQFHFHAP SEHTVNGKYYPLEMHLVHKDKDGNIAVIGVFFKEGKANPELDKVF KNALKEEGSKVEDGSININALLPPVKNYYTYCGSLTTPPCTEGVL WIVLKQPITASKQQIELFKSIMKHNNNRPTQPINCRYILESN (DNA) SEQIDNO:34 ATGAAACAACAGAAAAGACTGTATGCACGCCTGCTTACATTACTG TTTGCTCTTATTTTTCTTTTACCGCATTCAGCAGCGGCTGCCGG CGAACATGCAATTCTGCAGAAAAATGCGGAAGTCCATCATTGGAG CTATGAAGGCGAAAACGGACCGGAAAATTGGGCCAAACTGAACCC GGAATACTTTTGGTGCAACCTTAAAAACCAGTCTCCGGTCGATAT TTCAGATAACTACAAAGTTCATTGTAAACTGGAAAAACTGCATAT CAACTACAACAAAGCAGTTAACCCGGAAATTGTGAATAACGGACA TACAATCCAAGTTAACGTGTTAGAAGATTTTAAACTGAACATCAA AGGCAAAGAATACCATCTTAAACAGTTTCATTTTCATGCTCCGTC TGAACATACAGTGAACGGCAAATATTATCCGCTTGAAATGCATCT GGTCCATAAAGATAAAGATGGCAACATTGCAGTCATCGGAGTTTT CTTTAAAGAAGGCAAAGCGAACCCGGAACTTGATAAAGTTTTTAA AAACGCTCTGAAAGAAGAAGGAAGCAAAGTGTTTGATGGCTCTAT TAACATCAATGCGCTGCTTCCGCCGGTTAAAAACTACTACACATA CTGCGGAAGCTTAACAACACCGCCGTGTACAGAAGGCGTGCTGTG GATTGTCCTTAAACAACCGATCACAGCTTCTAAACAACAGATTGA ACTGTTTAAATCAATCATGAAACATAACAACAATAGACCGACACA GCCGATTAACTGTCGCTATATCCTGGAAAGCAATTAA

[0164] The foregoing discussion and examples have been presented for purposes of illustration and description. The foregoing is not intended to limit the aspects, embodiments, or configurations to the form or forms disclosed herein. In the foregoing Detailed Description for example, various features of the aspects, embodiments, or configurations are grouped together in one or more embodiments, configurations, or aspects for the purpose of streamlining the disclosure. The features of the aspects, embodiments, or configurations, may be combined in alternate aspects, embodiments, or configurations other than those discussed above. This method of disclosure is not to be interpreted as reflecting an intention that the aspects, embodiments, or configurations require more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive aspects lie in less than all features of a single foregoing disclosed embodiment, configuration, or aspect. While certain aspects of conventional technology have been discussed to facilitate disclosure of some embodiments of the present invention, the Applicants in no way disclaim these technical aspects, and it is contemplated that the claimed invention may encompass one or more of the conventional technical aspects discussed herein. The following claims are hereby incorporated into this Detailed Description, with each claim standing on its own as a separate aspect, embodiment, or configuration.